Dr. David M. King
Claim this profilePark Nicollet Clinic - Saint Louis Park
About David M. King
Education:
- Graduated from the University of Boulder School of Medicine, Boulder, CO.
- Completed Residency and Fellowship at the University of Wisconsin Medical School, Madison, WI.
Experience:
- Specializes in Medical Oncology & Hematology.
- Focus areas include Breast Cancer, Melanoma, and Prostate Cancer.
- Holds Board Certifications in Medical Oncology and Internal Medicine.
- Member of the American Society of Clinical Oncology (ASCO) and the American Society for Cancer Research.
Area of expertise
Lung Cancer
David M. King has run 17 trials for Lung Cancer. Some of their research focus areas include:
Breast Cancer
David M. King has run 16 trials for Breast Cancer. Some of their research focus areas include:
Affiliated Hospitals
Park Nicollet Clinic - Saint Louis Park
Regions Hospital
Clinical Trials David M. King is currently running
Financial Navigation
for Cancer Patients
This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, income and insurance. Financial hardship can lead to a delay or a stop in cancer care, and is linked to poor quality of life. Financial navigation programs, such as CostCOM, provide financial counseling, education and connections to appropriate resources to reduce financial barriers to healthcare and minimize financial stress and burden. CostCOM may improve adherence to care and decrease financial burden in patients with cancer.
Recruiting
1 award
N/A
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
More about David M. King
Clinical Trial Related
9 years of experience running clinical trials · Led 104 trials as a Principal Investigator · 41 Active Clinical Trials
Treatments David M. King has experience with
- Nivolumab
- Carboplatin
- Paclitaxel
- Pembrolizumab
- Radiation Therapy
- Cisplatin
Breakdown of trials David M. King has run
Lung Cancer
Breast Cancer
Breast cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David M. King specialize in?
David M. King focuses on Lung Cancer and Breast Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is David M. King currently recruiting for clinical trials?
Yes, David M. King is currently recruiting for 41 clinical trials in Saint Louis Park Minnesota. If you're interested in participating, you should apply.
Are there any treatments that David M. King has studied deeply?
Yes, David M. King has studied treatments such as Nivolumab, Carboplatin, Paclitaxel.
What is the best way to schedule an appointment with David M. King?
Apply for one of the trials that David M. King is conducting.
What is the office address of David M. King?
The office of David M. King is located at: Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota 55416 United States. This is the address for their practice at the Park Nicollet Clinic - Saint Louis Park.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.